These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17167274)

  • 1. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
    Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
    Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab modulates T cell function both in vivo and in vitro.
    Koszik F; Stary G; Selenko-Gebauer N; Stingl G
    J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
    Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
    Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
    Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
    Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.
    Coffey GP; Stefanich E; Palmieri S; Eckert R; Padilla-Eagar J; Fielder PJ; Pippig S
    J Pharmacol Exp Ther; 2004 Sep; 310(3):896-904. PubMed ID: 15190122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab.
    Kuschei WM; Leitner J; Majdic O; Pickl WF; Zlabinger GJ; Grabmeier-Pfistershammer K; Steinberger P
    Clin Immunol; 2011 May; 139(2):199-207. PubMed ID: 21414849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.
    Jullien D; Prinz JC; Langley RG; Caro I; Dummer W; Joshi A; Dedrick R; Natta P
    Dermatology; 2004; 208(4):297-306. PubMed ID: 15178911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
    Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
    BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.